LAVA Therapeutics N.V.
0.00%
0
1840748
N51517105
Sep 18, 2025
Sep 23, 2025, 04:52 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | Partnership | 0.00% | 0 | 0 | 0 |
| Versant Ventures VI GP, L.P. | Partnership | 0.00% | 0 | 0 | 0 |
| Versant Ventures VI GP-GP, LLC | Other | 0.00% | 0 | 0 | 0 |
| Versant Vantage I, L.P. | Partnership | 0.00% | 0 | 0 | 0 |
| Versant Vantage I GP, L.P. | Partnership | 0.00% | 0 | 0 | 0 |
| Versant Vantage I GP-GP, LLC | Other | 0.00% | 0 | 0 | 0 |
Disclosure Items (2)
Common Shares, par value Euro 0.12 per share
LAVA Therapeutics N.V.
Yalelaan 62, Utrecht, P7, 3584 CM
See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
On September 19, 2025, Versant VI sold 2,370,533 Common Shares at a weighted average price per share of $1.4014 for aggregate proceeds of approximately $3,322,064.95. On September 19, 2025, Vantage LP sold 532,870 Common Shares at a weighted average price per share of $1.4014 for aggregate proceeds of approximately $746,764.02.
As of September 19, 2025, the Reporting Persons ceased to beneficially own more than 5% of the Issuer's outstanding Common Shares.